• Je něco špatně v tomto záznamu ?

Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors

A. Kopkova, J. Sana, T. Machackova, M. Vecera, L. Radova, K. Trachtova, V. Vybihal, M. Smrcka, T. Kazda, O. Slaby, P. Fadrus,

. 2019 ; 11 (10) : . [pub] 20191012

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19044210

Grantová podpora
15-34553A Ministerstvo Zdravotnictví Ceské Republiky

Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19044210
003      
CZ-PrNML
005      
20200109095606.0
007      
ta
008      
200107s2019 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers11101546 $2 doi
035    __
$a (PubMed)31614872
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kopkova, Alena $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. alena.kopkova@ceitec.muni.cz.
245    10
$a Cerebrospinal Fluid MicroRNA Signatures as Diagnostic Biomarkers in Brain Tumors / $c A. Kopkova, J. Sana, T. Machackova, M. Vecera, L. Radova, K. Trachtova, V. Vybihal, M. Smrcka, T. Kazda, O. Slaby, P. Fadrus,
520    9_
$a Central nervous system (CNS) malignancies include primary tumors that originate within the CNS as well as secondary tumors that develop as a result of metastatic spread. Circulating microRNAs (miRNAs) were found in almost all human body fluids including cerebrospinal fluid (CSF), and they seem to be highly stable and resistant to even extreme conditions. The overall aim of our study was to identify specific CSF miRNA patterns that could differentiate among brain tumors. These new biomarkers could potentially aid borderline or uncertain imaging results onto diagnosis of CNS malignancies, avoiding most invasive procedures such as stereotactic biopsy or biopsy. In total, 175 brain tumor patients (glioblastomas, low-grade gliomas, meningiomas and brain metastases), and 40 non-tumor patients with hydrocephalus as controls were included in this prospective monocentric study. Firstly, we performed high-throughput miRNA profiling (Illumina small RNA sequencing) on a discovery cohort of 70 patients and 19 controls and identified specific miRNA signatures of all brain tumor types tested. Secondly, validation of 9 candidate miRNAs was carried out on an independent cohort of 105 brain tumor patients and 21 controls using qRT-PCR. Based on the successful results of validation and various combination patterns of only 5 miRNA levels (miR-30e, miR-140, let-7b, mR-10a and miR-21-3p) we proposed CSF-diagnostic scores for each tumor type which enabled to distinguish them from healthy donors and other tumor types tested. In addition to this primary diagnostic tool, we described the prognostic potential of the combination of miR-10b and miR-196b levels in CSF of glioblastoma patients. In conclusion, we performed the largest study so far focused on CSF miRNA profiling in patients with brain tumors, and we believe that this new class of biomarkers have a strong potential as a diagnostic and prognostic tool in these patients.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sana, Jiri $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. jiri.sana@ceitec.muni.cz. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic. jiri.sana@ceitec.muni.cz.
700    1_
$a Machackova, Tana $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. 375588@mail.muni.cz.
700    1_
$a Vecera, Marek $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. marek.vecera@ceitec.muni.cz.
700    1_
$a Radova, Lenka $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. 232848@mail.muni.cz.
700    1_
$a Trachtova, Karolina $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. trachtova@mail.muni.cz.
700    1_
$a Vybihal, Vaclav $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. Vybihal.Vaclav@fnbrno.cz. Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. Vybihal.Vaclav@fnbrno.cz.
700    1_
$a Smrcka, Martin $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. Smrcka.Martin@fnbrno.cz. Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. Smrcka.Martin@fnbrno.cz.
700    1_
$a Kazda, Tomas $u Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. tomas.kazda@mou.cz. Department of Radiation Oncology, Masaryk Memorial Cancer Institute, Faculty of Medicine, Masaryk University, Brno 656 53, Czech Republic. tomas.kazda@mou.cz.
700    1_
$a Slaby, Ondrej $u Central European Institute of Technology (CEITEC), Masaryk University, Brno 625 00, Czech Republic. ondrej.slaby@ceitec.muni.cz. Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno 656 53, Czech Republic. ondrej.slaby@ceitec.muni.cz.
700    1_
$a Fadrus, Pavel $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. fadrus.pavel@fnbrno.cz. Faculty of Medicine, Masaryk University, Brno 625 00, Czech Republic. fadrus.pavel@fnbrno.cz.
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 11, č. 10 (2019)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31614872 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200107 $b ABA008
991    __
$a 20200109095935 $b ABA008
999    __
$a ind $b bmc $g 1480799 $s 1082880
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 11 $c 10 $e 20191012 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 15-34553A $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20200107

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...